Valter Gattei

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

This paper introduces a Bayesian framework to predict tumour evolution and drug resistance using longitudinal cancer data across three cancer types.